DURHAM, NC -- (Marketwire) -- 11/10/09 -- Aldagen, Inc. today announced that data from clinical studies of ALD-201 and ALD-301 will be presented at the American Heart Association Scientific Sessions 2009 in Orlando, Florida. ALD-201 and ALD-301 are regenerative cell therapies being developed as treatments for ischemic heart failure and critical limb ischemia, respectively.

The titles, dates, and times of the presentations are as follows:

ALD-201

--  Session Title: Heart Failure: Cell and Gene Based Therapies I
--  Abstract Title: First In Man Transendocardial Injection of Autologous
    Aldehyde Dehydrogenase-Bright Cells in Heart Failure Patients (FOCUS-
    Bright)
--  Oral Session, Presenter: Emerson C. Perin,  MD, PhD, FACC, Director,
    New Cardiovascular Interventional Technology; Director, Clinical Research
    for Cardiovascular Medicine, Texas Heart Institute
--  Date/Time: Tuesday, November 17, 2009, 10:00 am ET
--  Location: Room W102
    

ALD-301

--  Session Title: Stem/Progenitor Cells: Translational Studies
--  Abstract Title: CLI-Bright: A Phase I Randomized Blinded Clinical
    Trial Comparing the Effect of Intramuscular Injection of Autologous Bone
    Marrow Derived Aldehyde Dehydrogenase Bright Cells and Mononuclear Stem
    Cells in Patients With Critical Limb Ischemia
--  Poster Session
--  Date/Time: Sunday, November 15, 2009, 9:30-11:00 am ET
--  Location: Poster Hall A2-A3, Core 7
    

About Aldagen, Inc.

Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. The company's most advanced product candidates are ALD-101, ALD-301 and ALD-201. Aldagen is currently conducting a pivotal Phase 3 clinical trial of ALD-101 for improving engraftment following umbilical cord blood transplants used to treat inherited metabolic diseases in pediatric patients. The company is also preparing to commence a pivotal Phase 3 clinical trial of ALD-301 in treating critical limb ischemia and is developing ALD-201 for the treatment of ischemic heart failure. Aldagen is pursuing the development of additional product candidates based on the company's proprietary technology for isolating adult stem cells that express high levels of ALDH, including products to improve engraftment following cord blood transplants used to treat leukemias, for the treatment of inherited metabolic diseases and for the post-acute treatment of ischemic stroke.